JHS Svendgaard Laboratories Ltd
JHS NSE
JHS Svendgaard Laboratories Ltd
Consumer GoodsNSE: JHS BSE: 532771 Personal Care
Key Fundamentals
MicrocapPersonal CareConsumer GoodsMarket Cap
₹76.83 Cr
Volatility
Moderate
P/E Ratio
-40
EBITDA
₹2.61 Cr
Return on Equity
-11.43%
Debt to Equity
0.09
Book Value
₹19.98
52W High
₹13.9
52W Low
₹6.26
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view JHS Svendgaard Laboratories Ltd insights
37 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company is almost debt free.
- Stock is trading at 0.45 times its book value
Weaknesses
6- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 0.18% over past five years.
- Promoter holding is low: 33.8%
- Company has a low return on equity of -4.75% over last 3 years.
- Earnings include an other income of Rs.2.55 Cr.
- Promoter holding has decreased over last 3 years: -8.38%
Growth Rate
Revenue Growth
7.15% ↗
Net Income Growth
-86.29% ↘
Cash Flow Change
43.57% ↗
ROE
378.24% ↗
ROCE
295.91% ↗
EBITDA Margin (Avg.)
-308.40% ↘
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.9 | 18.93 | 14.3 | 21.66 | 24.48 | 19.68 | 22.66 | 25.17 | 23.45 | 22.28 | 23.27 | 32.7 | 30.38 |
| Expenses | 18.02 | 18.52 | 14.36 | 20.82 | 22.51 | 20.52 | 22.41 | 30.55 | 21.79 | 21.37 | 21.6 | 34.34 | 28.31 |
| Operating Profit | -2.12 | 0.41 | -0.06 | 0.84 | 1.97 | -0.84 | 0.25 | -5.38 | 1.66 | 0.91 | 1.67 | -1.64 | 2.07 |
| OPM % | -13.33% | 2.17% | -0.42% | 3.88% | 8.05% | -4.27% | 1.1% | -21.37% | 7.08% | 4.08% | 7.18% | -5.02% | 6.81% |
| Other Income | 0.41 | 0.2 | 2.34 | 1.37 | 0.32 | 0.86 | 0.27 | -1.44 | 1 | 1.14 | 0.59 | 0.73 | 0.09 |
| Interest | 0.13 | 0.1 | 0.11 | 0.13 | 0.12 | 0.11 | 0.13 | 0.21 | 0.16 | 0.2 | 0.28 | 0.22 | 0.28 |
| Depreciation | 1.32 | 1.5 | 1.63 | 1.9 | 1.97 | 1.98 | 1.97 | 2.02 | 1.88 | 1.86 | 1.9 | 1.86 | 1.82 |
| PBT | -3.16 | -0.99 | 0.54 | 0.18 | 0.2 | -2.07 | -1.58 | -9.05 | 0.62 | -0.01 | 0.08 | -2.99 | 0.06 |
| Tax % | -18.35% | -26.26% | 100% | 516.67% | 415% | 398.07% | 15.82% | -23.09% | -69.35% | 1800% | -887.5% | 19.73% | -1716.67% |
| Net Profit | -2.59 | -0.73 | 0.01 | -0.75 | -0.63 | -10.32 | -1.84 | -6.96 | 1.06 | -0.2 | 0.79 | -3.57 | 1.09 |
| EPS in Rs | -0.4 | -0.09 | 0 | -0.1 | -0.08 | -1.21 | -0.21 | -0.81 | 0.12 | -0.02 | 0.09 | -0.41 | 0.12 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 55 | 100 | 104 | 140 | 124 | 139 | 101 | 86 | 85 | 71 | 92 | 102 | 109 |
| Expenses | 59 | 93 | 92 | 126 | 124 | 137 | 99 | 87 | 94 | 72 | 96 | 99 | 106 |
| Operating Profit | -4 | 7 | 12 | 14 | 0 | 2 | 2 | -1 | -9 | -1 | -4 | 3 | 3 |
| OPM % | -7% | 7% | 11% | 10% | 0.1% | 1.2% | 1.9% | -1% | -11% | -1.3% | -4.4% | 2.6% | 2.8% |
| Other Income | -6 | -17 | 0 | 32 | 6 | 3 | 7 | 9 | -7 | 4 | 0 | 3 | 3 |
| Interest | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| Depreciation | 12 | 10 | 6 | 7 | 7 | 9 | 7 | 7 | 6 | 6 | 8 | 8 | 7 |
| PBT | -22 | -22 | 5 | 38 | -2 | -6 | 1 | 0 | -23 | -3 | -13 | -2 | -3 |
| Tax % | 0% | 0% | -327% | 32% | -19% | -17% | -39% | 4000% | -24% | 18% | 58% | -16% | — |
| Net Profit | -22 | -22 | 22 | 26 | -2 | -5 | 1 | -4 | -18 | -4 | -20 | -2 | -2 |
| EPS in Rs | -9.2 | -5.76 | 4.98 | 4.29 | -0.11 | -0.33 | 0.19 | -0.62 | 0.62 | -0.52 | -2.31 | -0.22 | -0.22 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 38 | 44 | 61 | 61 | 61 | 64 | 65 | 78 | 78 | 86 | 87 |
| Reserves | 96 | 63 | 90 | 113 | 116 | 117 | 124 | 121 | 95 | 91 | 87 | 87 |
| Borrowings | 19 | 3 | 2 | 2 | 7 | 9 | 7 | 6 | 3 | 5 | 6 | 15 |
| Other Liabilities | 33 | 19 | 19 | 32 | 39 | 55 | 33 | 30 | 52 | 22 | 25 | 26 |
| Total Liabilities | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 | 215 |
| Fixed Assets | 108 | 65 | 65 | 71 | 71 | 66 | 63 | 59 | 65 | 90 | 90 | 89 |
| CWIP | 0 | 1 | 1 | 1 | 5 | 7 | 9 | 20 | 9 | 1 | 0 | 4 |
| Investments | 0 | 0 | 1 | 18 | 10 | 6 | 2 | 4 | 3 | 3 | 4 | 5 |
| Other Assets | 63 | 57 | 89 | 118 | 137 | 163 | 154 | 140 | 152 | 102 | 110 | 117 |
| Total Assets | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 | 215 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 7 | -4 | -4 | 14 | -11 | 10 | 12 | -9 | 23 | -9 | -5 | -3 |
| Investing | 1 | 1 | -3 | -27 | -7 | -11 | -2 | -5 | 10 | -21 | -20 | -12 |
| Financing | -10 | 4 | 10 | 14 | 13 | 0 | 10 | -2 | -1 | 2 | 23 | 11 |
| Net Cash Flow | -1 | 2 | 3 | 0 | -5 | 0 | 20 | -16 | 32 | -28 | -2 | -3 |
| Free Cash Flow | 9 | -7 | -17 | 3 | -26 | 0 | 5 | -16 | 21 | -33 | -14 | -15 |
| CFO/OP | -189 | -58 | -33 | 119 | -10,000 | 595 | 650 | 1,051 | -257 | 1,001 | 122 | -77 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 167 | 25 | 48 | 111 | 158 | 252 | 213 | 77 | 80 | 66 | 52 | 60 |
| Inventory Days | 94 | 53 | 95 | 65 | 60 | 30 | 97 | 114 | 128 | 176 | 153 | 85 |
| Days Payable | 106 | 67 | 123 | 153 | 134 | 177 | 128 | 130 | 197 | 197 | 141 | 100 |
| Cash Conversion Cycle | 156 | 12 | 19 | 23 | 85 | 105 | 182 | 61 | 11 | 46 | 63 | 45 |
| Working Capital Days | -39 | 58 | 56 | 122 | 173 | 198 | 272 | 217 | 41 | 51 | 48 | 42 |
| ROCE % | -12% | -3% | 5% | 8% | 0% | 4% | 1% | 1% | -2% | -2% | -5% | -1% |
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - JHS Svendgaard files Large Corporate disclosure; confirms not a large corporate, outstanding borrowing was 13.87 Cr on 31 March 2026. 30 Apr - JHS Svendgaard files Large Corporate disclosure; confirms not a large corporate, outstanding borrowing was 13.87 Cr on 31 March 2026.
2
Announcement under Regulation 30 (LODR)-Change in RTA
27 Apr - JHS Svendgaard changed RTA from Alankit to Beetal, effective 27 April 2026. 27 Apr - JHS Svendgaard changed RTA from Alankit to Beetal, effective 27 April 2026.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - JHS Svendgaard files Large Corporate disclosure; confirms not a large corporate, outstanding borrowing was 13.87 Cr on 31 March 2026. 30 Apr - JHS Svendgaard files Large Corporate disclosure; confirms not a large corporate, outstanding borrowing was 13.87 Cr on 31 March 2026.
4
Announcement under Regulation 30 (LODR)-Change in RTA
10h - JHS Svendgaard changed RTA from Alankit to Beetal, effective 27 April 2026. 10h - JHS Svendgaard changed RTA from Alankit to Beetal, effective 27 April 2026.
5
Announcement under Regulation 30 (LODR)-Change in RTA
15 Apr - RTA changed from Alankit Assignments to Beetal Financial; effective date to be intimated later. 15 Apr - RTA changed from Alankit Assignments to Beetal Financial; effective date to be intimated later.
Frequently Asked Questions about JHS Svendgaard Laboratories Ltd
What does JHS Svendgaard Laboratories Ltd do?
Incorporated in 1997, JHS Svendgaard Laboratories Ltd does manufacturing of
oral and dental products for national and international brands[1]
Where is JHS Svendgaard Laboratories Ltd (JHS) listed?
JHS Svendgaard Laboratories Ltd is listed on the Indian stock exchanges. It is listed on NSE: JHS and BSE: 532771. You can view its live share price, financials, and ratios on Tapetide.
Which sector does JHS Svendgaard Laboratories Ltd belong to?
JHS Svendgaard Laboratories Ltd operates in the Consumer Goods sector within the Personal Care industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of JHS Svendgaard Laboratories Ltd?
JHS Svendgaard Laboratories Ltd has a market capitalisation of approximately ₹76.83 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of JHS Svendgaard Laboratories Ltd?
The Price-to-Earnings (PE) ratio of JHS Svendgaard Laboratories Ltd is -40.00. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of JHS Svendgaard Laboratories Ltd?
Over the past 52 weeks, JHS Svendgaard Laboratories Ltd has traded between a low of ₹6.26 and a high of ₹13.9. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of JHS Svendgaard Laboratories Ltd?
JHS Svendgaard Laboratories Ltd has a Return on Equity (ROE) of -11.43%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research JHS Svendgaard Laboratories Ltd on Tapetide?
On Tapetide, you can view JHS Svendgaard Laboratories Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1997, JHS Svendgaard Laboratories Ltd does manufacturing of oral and dental products for national and international brands[1]
Website svendgaard.com
CEO Mr. Nikhil Nanda
Employees 263
Listed 2006-10-21
Face Value ₹ 10
Issued Size 8,56,03,966